Evaluation of relative promoter strength in primary hepatocytes using optimized lipofection

Katherine Parker Ponder, Robert P. Dunbar, Deborah R. Wilson, Gretchen J. Darlington, Savio L.C. Woo

Research output: Contribution to journalArticlepeer-review

96 Scopus citations

Abstract

For most genetic deficiencies manifested in the liver, maximization of gene expression in hepatocytes will be an important factor in achieving successful gene therapy. A rapid, highly efficient, and non toxic method for transfecting DNA into hepatocytes was used to compare directly promoter strengths of various cellular and viral promoters. Conditions are described here for transfecting 5-10% of primary hepatocytes using the positively charged liposomes, Lipofectin. Cells are not damaged by this method as they continue to transcribe genes controlled by liver specific promoters and can survive for over 2 weeks in culture. We find that the cytomegalovirus, SRα, and β-actin promoters are more active than the SV40, RSV, RNA polymerase II, albumin, α1-antitrypsin, or phosphoenolpyruvate carboxykinase promoters. A simple TK promoter and a TK promoter with the polyoma enhancer (MCI) were almost completely inactive. This information will be useful in the construction of vectors designed to express genes efficiently in primary hepatocytes for purposes of gene therapy, although the stability of expression from these promoters will need to be demonstrated in hepatocytes in vivo.

Original languageEnglish
Pages (from-to)41-52
Number of pages12
JournalHuman Gene Therapy
Volume2
Issue number1
DOIs
StatePublished - 1991

Fingerprint

Dive into the research topics of 'Evaluation of relative promoter strength in primary hepatocytes using optimized lipofection'. Together they form a unique fingerprint.

Cite this